Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with a contract to manufacture a novel live attenuated […]
Snyder, Founder of Florida Biologix, Named Innovator of the Year for 2020
When informed that he was the recipient of “Innovator of the Year” – the highest recognition that UF Innovate | Tech Licensing bestows – Dr. Richard Snyder smiled humbly and said that he was caught off guard by the nomination. In 2006, the University of Florida innovator founded Florida Biologix in Alachua to provide drug-development […]
ABEC Supporting Ology Bioservices COVID-19 Therapeutic Manufacturing Programs
ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, announced it is delivering process systems to UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), to support their production of critical vaccines and therapeutics for COVID-19. ABEC is providing […]
entrinsic bioscience Secures U.S. Patent Grant for Breakthrough Respiratory Disease Program
UF startup and UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has been granted U.S. Patent No. (USPN) 10,758,507 (‘507 patent) for novel therapeutic formulations in the treatment of a range of respiratory diseases with significant unmet medical needs. EBS is […]
SATLANTIS Will Launch Its Second Nano-Camera Into Space in 2022
UF startup and UF Innovate | The Hub resident company SATLANTIS, a provider of high-performance payload technologies for Earth observation and remote sensing, will launch its second nano-camera into space in 2022. The plans were announced during the annual meeting held in Bilbao, Spain, by its Advisory Council, which is proud of the success achieved in the first […]
Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park
Gainesville-based developer Concept Companies has completed construction on a new 12,950-square-foot office and lab building in Copeland Park for UF startup and UF Innovate | Sid Martin Biotech alum Lacerta Therapeutics, a clinical-stage gene therapy company. With its official move-in date on July 27, 2020, Lacerta Therapeutics is the newest tenant in Alachua’s Copeland Park. […]
UF Based Company Develops Technology for Cheaper Tech Screens to Sell Globally
You might not think much about how your phone or TV screen works the way it does. As you can guess, there’s plenty of technology behind it–literally. One group of University of Florida graduates have built a company around that technology. It’s called Mattrix Technologies, a UF startup and UF Innovate | The Hub resident […]
AGTC Joins the My Retina Tracker Program as a New Scientific Collaborator
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announced that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, will join the My Retina Tracker Program as a new scientific collaborator […]
AbFero Announces PK Study Results for SP-420 in Transfusional Iron Overload – Proceeds With Phase 1–2 Trial of Iron Chelator
UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced it completed analysis of a 12-patient normal volunteer pharmacokinetic (PK) trial of its lead iron chelator, SP-420. The PK data confirmed that the doses of SP-420 planned for the company’s upcoming Phase 1-2 trial in patients with […]
TheraVab Biosciences Announces Exclusive Option to License Engineered Receptor Immunobiotherapy for the Treatment of Neu
TheraVab Biomedics Pte. Ltd., a pre-clinical stage immunotherapy company that aims at reversal of the inflammatory processes that lead to cancers, neurodegenerative ailments and cardiovascular disorders, announced that it has entered into an agreement with the University of Florida Research Foundation for the exclusive option to license decoy receptor technology for the development of an […]